Disclosed are thieno[3,2-d]pyrimidin-4-one and thieno[2,3-d]pyrimidin-4-one derivatives as represented by the general formula (I), wherein one of Q1, Q2 or Q3 is S, and the other two are -CR1- Z is a bond, O, NR2, alkylene or heteroalkylene R3 is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, each of which is optionally substituted with up to three R1, or R3 can be hydrogen if Z is not a bond L is selected from the group consisting of -C(R2)2-, -C(R2)2-C(R2)2-, -C(R2)2-NR2- or -C(R2)2-S(O)n- Het is a monocyclic aromatic or bicyclic aromatic ring system wherein at least two ring atoms are N, and Het is optionally substituted with up to three substituents and wherein the remaining substituents are as defined herein. Further disclosed is a pharmaceutical composition which comprises a compound as defined above for the treatment conditions such as cancer, leukaemia, inflammatory disorders, immune disorders or hypertension.
